Epidemiology, risk factors and management of paediatric diabetic retinopathy

British Journal of Ophthalmology

Volumn 96, Issue 3, 2012, Pages 312-317

  Sultan, Marla B ^a,b   Starita, Carla ^c   Huang, Kui ^a  

^a PFIZER INC   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; LIPID; VASCULOTROPIN INHIBITOR;

ADULTHOOD; ATHEROSCLEROSIS; CARBOHYDRATE ANALYSIS; CLINICAL FEATURE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; GENETIC ASSOCIATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEREDITY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LIPID BLOOD LEVEL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OPHTHALMOSCOPY; PATHOPHYSIOLOGY; PREPUBERTY; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSORY SYSTEM PARAMETERS;

ADOLESCENT; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; GLYCEMIC INDEX; HUMANS; INCIDENCE; INFANT; RISK FACTORS;

EID: 84857114722     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300169     Document Type: Review

References (113)

1. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63. (Pubitemid 38456292)
2. Brink SJ. Complications of pediatric and adolescent type 1 diabetes mellitus. Curr Diab Rep 2001;1:47-55.
3. Gallego PH, Wiltshire E, Donaghue KC. Identifying children at particular risk of long-term diabetes complications. Pediatr Diabetes 2007;8(Suppl 6):40-8. (Pubitemid 47323766)
4. Donaghue KC, Chiarelli F, Trotta D, et al. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl 12):195-203.
5. Kernell A, Dedorsson I, Johansson B, et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. Diabetologia 1997;40:307-10. (Pubitemid 27096555)
6. Hamilton J, Brown M, Silver R, et al. Early onset of severe diabetes mellitus-related microvascular complications. J Pediatr 2004;144:281-3. (Pubitemid 38869410)
7. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006;29:1300-6. (Pubitemid 44125926)
8. McNally PG, Raymond NT, Swift PG, et al. Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med 1993;10:906-8. (Pubitemid 23358996)
9. Bognetti E, Calori G, Meschi F, et al. Prevalence and correlations of early microvascular complications in young type I diabetic patients: role of puberty. J Pediatr Endocrinol Metab 1997;10:587-92. (Pubitemid 28047365)
10. Holl R, Lang GE, Grabert M, et al. Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. J Pediatr 1998;132:790-4. (Pubitemid 28232928)
11. Olsen BS, Sjølie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 2004;18:160-4. (Pubitemid 38622544)
12. Donaghue KC, Craig ME, Chan AK, et al. Prevalence of diabetes complications 6 years after diagnosis in an incident cohort of childhood diabetes. Diabet Med 2005;22:711-18. (Pubitemid 40805891)
13. Majaliwa ES, Munubhi E, Ramaiya K, et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care 2007;30:2187-92. (Pubitemid 47359012)
14. Massin P, Erginay A, Mercat-Caudal I, et al. Prevalence of diabetic retinopathy in children and adolescents with type-1 diabetes attending summer camps in France. Diabetes Metab 2007;33:284-9.
15. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994;125:177-88.
16. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010;59:1244-53.
17. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005;146:693-700. (Pubitemid 40616257)
18. Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med 2006;160:523-8.
19. Rosenbloom AL, Silverstein JH, Amemiya S, et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl 12):17-32.
20. Mohsin F, Craig ME, Cusumano J, et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005;28:1974-80. (Pubitemid 41060972)
21. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care 2011;34(Suppl 2):S120-7.
22. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369:1823-31. (Pubitemid 46783022)
23. Scott A, Toomath R, Bouchier D, et al. First national audit of the outcomes of care in young people with diabetes in New Zealand: high prevalence of nephropathy in Maori and Pacific Islanders. N Z Med J 2006;119:U2015.
24. McGrath NM, Parker GN, Dawson P. Early presentation of type 2 diabetes mellitus in young New Zealand Maori. Diabetes Res Clin Pract 1999;43:205-9. (Pubitemid 29202132)
25. Farah SE, Wals KT, Friedman IB, et al. Prevalence of retinopathy and microalbuminuria in pediatric type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2006;19:937-42. (Pubitemid 44349749)
26. Krakoff J, Hanson RL, Kobes S, et al. Comparison of the effect of plasma glucose concentrations on microvascular disease between Pima Indian youths and adults. Diabetes Care 2001;24:1023-8. (Pubitemid 33716370)
27. Lueder GT, Silverstein J; American Academy of Pediatrics Section on Ophthalmology and Section on Endocrinology. Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. Pediatrics 2005;116:270-3.
28. Maguire A, Chan A, Cusumano J, et al. The case for biennial retinopathy screening in children and adolescents. Diabetes Care 2005;28:509-13. (Pubitemid 40315305)
29. Skrivarhaug T, Fosmark DS, Stene LC, et al. Low cumulative incidence of proliferative retinopathy in childhood-onset type 1 diabetes: a 24-year follow-up study. Diabetologia 2006;49:2281-90. (Pubitemid 44359088)
30. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6. (Pubitemid 14127838)
31. Weinzimer SA, Doyle EA, Tamborlane WV Jr. Disease management in the young diabetic patient: glucose monitoring, coping skills, and treatment strategies. Clin Pediatr (Phila) 2005;44:393-403. (Pubitemid 40868901)
32. Danne T, Becker D. Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes. Acta Paediatr 2007;96:1560-70. (Pubitemid 47609783)
33. Kakleas K, Kandyla B, Karayianni C, et al. Psychosocial problems in adolescents with type 1 diabetes mellitus. Diabetes Metab 2009;35:339-50.
34. Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr 2010;22:405-11.
35. Ohmann S, Popow C, Rami B, et al. Cognitive functions and glycemic control in children and adolescents with type 1 diabetes. Psychol Med 2010;40:95-103.
36. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
37. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the diabetes control and complications trial (DCCT). J Pediatr 2001;139:804-12.
38. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008;126:1707-15.
39. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-80. (Pubitemid 29153089)
40. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-11. (Pubitemid 43334362)
41. Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes. Diabetes Care 2003;26:349-54.
42. Kostraba JN, Dorman JS, Orchard TJ, et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 1989;12:686-93. (Pubitemid 19284091)
43. Danne T, Kordonouri O, Hövener G, et al. Diabetic angiopathy in children. Diabet Med 1997;14:1012-25. (Pubitemid 28015385)
44. Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetic complications? Diabetes Care 2003;26:1224-9. (Pubitemid 36929276)
45. Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care 1990;13:1034-8. (Pubitemid 20333923)
46. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13.
47. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
48. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
49. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64. (Pubitemid 30185779)
50. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97. (Pubitemid 34175478)
51. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-93.
52. Beulens JW, Patel A, Vingerling JR, et al; on behalf of the AdRem project team and ADVANCE management committee. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009;52:2027-36.
53. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
54. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. (Pubitemid 350100775)
55. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
56. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.
57. Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs 2010;70:2171-200.
58. Kordonouri O, Danne T, Hopfenmüller W, et al. Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr 1996;85:43-8. (Pubitemid 26043204)
59. Gallego PH, Craig ME, Hing S, et al. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008;337:a918.
60. Fletcher EL, Phipps JA, Ward MM, et al. The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010;29:284-311.
61. Sjølie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract 2011;65:148-53.
62. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008;57:2191-8.
63. Schupp M, Janke J, Clasen R, et al. Angiotensin type q1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7. (Pubitemid 38620211)
64. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007;48:4342-50. (Pubitemid 351261068)
65. Kim JH, Kim JH, Yu YS, et al. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab 2009;29:621-8.
66. Miller AG, Tan G, Binger KJ, et al. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 2010;59:3208-15.
67. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-52. (Pubitemid 351519698)
68. Berg TJ, Dahl-Jorgensen K, Torjesen PA, et al. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 1997;20:1006-8. (Pubitemid 27224954)
69. Chiarelli F, de Martino M, Mezzetti A, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999;134:486-91. (Pubitemid 30180632)
70. Craig ME, Duffin AC, Gallego PH, et al. Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. Diabetes Care 2008;31:1201-6.
71. Wiltshire EJ, Gent R, Hirte C, et al. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002;51:2282-6. (Pubitemid 34729036)
72. MacKenzie KE, Wiltshire EJ, Gent R, et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics 2006;118:242-53. (Pubitemid 46071168)
73. Głowińska-Olszewska B, Urban M, Urban B, et al. The association of early atherosclerosis and retinopathy in adolescents with type 1 diabetes: preliminary report. Acta Diabetol 2007;44:131-7. (Pubitemid 47313095)
74. Nicoloff G, Petrova Ch, Christova P, et al. Detection of free elastin-derived peptides among diabetic children. Atherosclerosis 2007;192:342-7. (Pubitemid 46726337)
75. Cheung N, Rogers SL, Donaghue KC, et al. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care 2008;31:1842-6.
76. Bronson-Castain KW, Bearse MA Jr, Neuville J, et al. Adolescents with type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina 2009;29:618-26.
77. Cheung N, Donaghue KC, Liew G, et al. Quantitative assessment of early diabetic retinopathy using fractal analysis. Diabetes Care 2009;32:106-10.
78. Lim SW, Cheung N, Wang JJ, et al. Retinal vascular fractal dimension and risk of early diabetic retinopathy: a prospective study of children and adolescents with type 1 diabetes. Diabetes Care 2009;32:2081-3.
79. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 2009;49:35-52.
80. Ng DP. Human genetics of diabetic retinopathy: current perspectives. J Ophthalmol 2010;2010:172593.
81. Kao YL, Donaghue K, Chan A, et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 1998;83:2589-92. (Pubitemid 28503069)
82. Kao YL, Donaghue K, Chan A, et al. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999;48:1338-40. (Pubitemid 29241035)
83. Hofer SE, Bennetts B, Chan AK, et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications 2006;20:322-8. (Pubitemid 44292534)
84. Wiltshire EJ, Mohsin F, Chan A, et al. Methylenetetrahydrofolate reductase and methionine synthase reductase gene polymorphisms and protection from microvascular complications in adolescents with type 1 diabetes. Pediatr Diabetes 2008;9:348-53.
85. Myśliwska J, Zorena K, Myśliwiec M, et al. The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res 2009;66:341-5.
86. Hovnik T, Dolzan V, Bratina NU, et al. Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. Diabetes Care 2009;32:2258-62.
87. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88. (Pubitemid 35386893)
88. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55. (Pubitemid 37536961)
89. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540-53. (Pubitemid 39281419)
90. Starita C, Patel M, Katz B, et al. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 2007;39:122-48.
91. Bittner C, Kordonouri O, Danne T. Diabetic retinopathy in children and adolescents with type 1 diabetes. In: Chiarelli F, Dahl-Jørgensen K, Kiess W, eds. Diabetes in Childhood and Adolescence. Pediatric and Adolescent Medicine. Vol. 10. Basel, Switzerland: Karger Publishing Company, 2005:314-28.
92. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9. (Pubitemid 36976059)
93. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84.
94. Senger DR, Connolly DT, Van de Water L, et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-8. (Pubitemid 20098819)
95. Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep 2008;8:263-9.
96. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
97. Wirostko B, Wong TY, Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008;27:608-21.
98. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998;21:143-56. (Pubitemid 28030402)
99. Lang GE. Laser treatment of diabetic retinopathy. Dev Ophthalmol 2007;39:48-68.
100. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
101. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. Retina 2009;29:1436-43.
102. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
103. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18.
104. Gardner TW, Antonetti DA, Barber AJ, et al. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47(Suppl 2):S253-62. (Pubitemid 36351245)
105. Georgakopoulos CD, Eliopoulou MI, Exarchou AM, et al. Decreased contrast sensitivity in children and adolescents with type 1 diabetes mellitus. J Pediatr Ophthalmol Strabismus 2011;48:92-7.
106. Verrotti A, Lobefalo L, Chiarelli F, et al. Colour vision and persistent microalbuminuria in children with type-1 (insulin-dependent) diabetes mellitus: a longitudinal study. Diabetes Res Clin Pract 1995;30:125-30. (Pubitemid 26076840)
107. Lobefalo L, Verrotti A, Mastropasqua L, et al. Blue-on-yellow and achromatic perimetry in diabetic children without retinopathy. Diabetes Care 1998;21:2003-6. (Pubitemid 28478308)
108. Bronson-Castain KW, Bearse MA Jr, Han Y, et al. Association between multifocal ERG implicit time delays and adaptation in patients with diabetes. Invest Ophthalmol Vis Sci 2007;48:5250-6. (Pubitemid 351260938)
109. Cantrill HL. The diabetic retinopathy study and the early treatment diabetic retinopathy study. Int Ophthalmol Clin 1984;24:13-29.
110. American Academy of Ophthalmology. Clinical report. Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. http://one.aao.org/CE/PracticeGuidelines/ClinicalStatements.aspx?sid= ab789157-5312-4bbe-86ed-8d164ffa9567 (accessed 27 Jul 2011).
111. Lucentis (ranibizumab) Product Information. Genentech Inc, 2010. http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf (accessed 27 Jul 2011).
112. Valent D, Pestak K, Otis M, et al. Type 2 diabetes in the pediatric population: are we meeting ADA clinical guidelines in Ohio? Clin Pediatr 2010;49:316-22.
113. Rosenberg JB, Friedman IB, Gurland JE. Compliance with screening guidelines for diabetic retinopathy in a large academic children's hospital in the Bronx. J Diabetes Complications 2011;25:222-6.